Cutaneous wound healing in normal hosts follows an orderly clinical process. The scientific underpinnings for healing are better understood than ever, although much remains to be discovered. Eventually, such improved understanding of cellular and subcellular physiology may lead to new or better forms of therapy for patients with acute, chronic, and surgical skin wounds.
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of human cancer and has an increasing annual incidence. Although most cSCC is cured with office-based therapy, advanced cSCC poses a significant risk for morbidity, impact on quality of life, and death. This document provides evidence-based recommendations for the management of patients with cSCC. Topics addressed include biopsy techniques and histopathologic assessment, tumor staging, surgical and nonsurgical management, follow-up and prevention of recurrence, and management of advanced disease. The primary focus of these recommendations is on evaluation and management of primary cSCC and localized disease, but where relevant, applicability to recurrent cSCC is noted, as is general information on the management of patients with metastatic disease.
Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curative. In these evidence-based guidelines of care, we provide recommendations for the management of patients with BCC, as well as an in-depth review of the best available literature in support of these recommendations. We discuss biopsy techniques for a clinically suspicious lesion and offer recommendations for the histopathologic interpretation of BCC. In the absence of a formal staging system, the best available stratification based on risk for recurrence is reviewed. With regard to treatment, we provide recommendations on treatment modalities along a broad therapeutic spectrum, ranging from topical agents and superficially destructive modalities to surgical techniques and systemic therapy. Finally, we review the available literature and provide recommendations on prevention and the most appropriate follow-up for patients in whom BCC has been diagnosed. ( J Am Acad Dermatol
Objective
To determine population-based incidence estimates of BCC and cSCC.
Patients and Methods
We reviewed the medical records of a population-based cohort diagnosed with nonmelanoma skin cancer between January 2, 2000 and December 31, 2010. Sex- and age-adjusted incidence rates were calculated and compared to estimates from previous periods.
Results
The age-adjusted BCC incidence per 100,000 persons was 360.0 (95% CI, 342.5–377.4) for men and 292.9 (95% CI, 278.6–307.1) for women. The age-adjusted cSCC incidence per 100,000 persons was 207.5 (95% CI, 193.9–221.1) for men and 128.8 (95% CI, 119.4–138.2) for women. From years 1976–1984 to 2000–2010, the age- and sex-adjusted BCC incidence per 100,000 persons increased from 222.0 (95% CI, 204.5–239.5) to 321.2 (95% CI, 310.3–332.2), and from 61.8 (95% CI, 52.3–71.4) to 162.5 (95% CI, 154.6–170.3) for cSCC. Over time, the anatomical distribution of BCC shifted from the head and neck to the torso, and cSCC shifted from the head and neck to the extremities.
Conclusions
The incidences of BCC and cSCC are increasing, with a disproportionate increase in cSCC relative to BCC. There is also a disproportionate increase in women of both tumors, and shifting of anatomical distributions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.